Keywords: سرطان متاستاتیک سینه; Breast cancer; HER-2-negative; Resistance; Biologic targeted agent; Combination therapy; ABC; advanced breast cancer; AE; adverse event; AI; aromatase inhibitor; AKT; protein kinase; BC; breast cancer; CDK; cyclin-dependent kinase; CT; chemotherapy; CTLA;
مقالات ISI سرطان متاستاتیک سینه (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: سرطان متاستاتیک سینه; Metastatic breast cancer; Intrinsic subtypes; Endocrine therapy; Targeted therapy; Chemotherapy; ABC guidelines;
Keywords: سرطان متاستاتیک سینه; Cryotherapy; Metastatic breast cancer; Cryo-immunotherapy; Dendritic cell-cytokine-induced killer cell; Chemotherapy;
Keywords: سرطان متاستاتیک سینه; Metastatic breast cancer; Estrogen receptor; Progesterone receptor; HER2; Technical bias;
Keywords: سرطان متاستاتیک سینه; Anthracyclines; Her2; Metastatic breast cancer; Overall survival; Palliative chemotherapy;
Keywords: سرطان متاستاتیک سینه; Metastatic breast cancer; Polysomnography; Sleep quality; Sleep architecture; Depression; Women;
Keywords: سرطان متاستاتیک سینه; Metastatic breast cancer; Supportive care; Palliative care; Site-specific metastasis; Low- and middle-income countries; Resource allocations;
Keywords: سرطان متاستاتیک سینه; Cytotoxic chemotherapy; Docetaxel; Metastatic breast cancer; Nab-paclitaxel; Solvent-based paclitaxel; Taxanes
Impact of body mass index on the clinical outcomes of patients with HER2-positive metastatic breast cancer
Keywords: سرطان متاستاتیک سینه; Metastatic breast cancer; HER2-positive; Body mass index; Trastuzumab;
Single-Agent Oral Vinorelbine as First-Line Chemotherapy for Endocrine-Pretreated Breast Cancer With Bone Metastases and No Visceral Involvement: NORBREAST-228 Phase II Study
Keywords: سرطان متاستاتیک سینه; Bone metastases; Hormone sensitive; Metastatic breast cancer; Oral chemotherapy; Vinorelbine;
Geriatric assessment and biomarkers in patients with metastatic breast cancer receiving first-line mono-chemotherapy: Results from the randomized phase III PELICAN trial
Keywords: سرطان متاستاتیک سینه; Geriatric assessment; Biomarker; Metastatic breast cancer; Prognostic factor; Pegylated liposomal doxorubicin; Anthracycline; Capecitabine; Elderly;
Quality-Adjusted Survival With nab-Paclitaxel Versus Standard Paclitaxel in Metastatic Breast Cancer: A Q-TWiST Analysis
Keywords: سرطان متاستاتیک سینه; Chemotherapy; Metastatic breast cancer; nab-Paclitaxel; Taxanes; Quality-adjusted time without symptoms of disease progression or toxicity of treatment;
First-line paclitaxel and cisplatin used sequentially or in combination in metastatic breast cancer: A phase II randomized study
Keywords: سرطان متاستاتیک سینه; Metastatic breast cancer; Chemotherapy; Combination; Sequential; Paclitaxel; Cisplatin;
Controversies in monitoring metastatic breast cancer during systemic treatment. Results of a GIM (Gruppo Italiano Mammella) survey
Keywords: سرطان متاستاتیک سینه; Drug monitoring; Metastatic breast cancer; Health resources; Stress; Psychological;
Circulating CD8+CD28â suppressor T cells tied to poorer prognosis among metastatic breast cancer patients receiving adoptive T-cell therapy: A cohort study
Keywords: سرطان متاستاتیک سینه; CD8+CD28â suppressor T cells; metastatic breast cancer; prognosis; prospective cohort study; adoptive cell immunotherapy;
Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort
Keywords: سرطان متاستاتیک سینه; Metastatic breast cancer; Overall survival; Subtypes; HER2;
Intérêt clinique de la détection des mutations circulantes d'ESR1 chez les patientes traitées pour un cancer du sein métastatique exprimant les récepteurs hormonaux
Keywords: سرطان متاستاتیک سینه; Mutations ESR1; Biopsie liquide; Cancer du sein métastatique; Hormonothérapie; ESR1 mutations; Liquid biopsy; Metastatic breast cancer; Hormone therapy;
Phase I feasibility study for intrathecal administration of trastuzumab in patients with HER2 positive breast carcinomatous meningitis
Keywords: سرطان متاستاتیک سینه; Metastatic breast cancer; Carcinomatous meningitis; Trastuzumab; Intrathecal therapy;
Fulvestrant plus goserelin versus anastrozole plus goserelin versus goserelin alone for hormone receptor-positive, HER2-negative tamoxifen-pretreated premenopausal women with recurrent or metastatic breast cancer (KCSG BR10-04): a multicentre, open-label,
Keywords: سرطان متاستاتیک سینه; Metastatic breast cancer; Premenopausal; Fulvestrant; Endocrine therapy;
Progression-free Survival With First-line Endocrine-based Therapies Among Postmenopausal Women With HR+/HER2- Metastatic Breast Cancer:
Keywords: سرطان متاستاتیک سینه; endocrine therapy; HR positive/HER2 negative; metastatic breast cancer; network meta-analysis; progression-free survival; targeted therapy;
BRCA2 Reversion Mutation Associated With Acquired Resistance to Olaparib in Estrogen Receptor-positive Breast Cancer Detected by Genomic Profiling of Tissue and Liquid Biopsy
Keywords: سرطان متاستاتیک سینه; BRCA reversion; Circulating tumor DNA; ctDNA; Metastatic breast cancer; PARP inhibitor;
Characteristics and Prognostic Factors for Patients With HER2-overexpressing Breast Cancer and Brain Metastases in the Era of HER2-targeted Therapy: An Argument for Earlier Detection
Keywords: سرطان متاستاتیک سینه; Breast cancer epidemiology; Central nervous system metastasis; HER2-positive; Metastatic breast cancer; Prognosis;
Role of Fludeoxyglucose in Breast Cancer
Keywords: سرطان متاستاتیک سینه; FDG-PET/CT; Breast cancer; Treatment response; Neoadjuvant chemotherapy; Metastatic breast cancer;
Phase II Study of Paclitaxel and Dasatinib in Metastatic Breast Cancer
Keywords: سرطان متاستاتیک سینه; Advanced breast cancer; Dasatinib; Metastatic breast cancer; Paclitaxel; SRC;
T-DM1 and brain metastases: Clinical outcome in HER2-positive metastatic breast cancer
Keywords: سرطان متاستاتیک سینه; Brain metastases; Metastatic breast cancer; T-DM1; Trastuzumab-emtansine;
Single-nucleotide polymorphisms in the genes of CES2, CDA and enzymatic activity of CDA for prediction of the efficacy of capecitabine-containing chemotherapy in patients with metastatic breast cancer
Keywords: سرطان متاستاتیک سینه; 5â²DFCR; 5â²deoxy-5-fluorocytidine; 5â²DFUR; 5â²-deoxy-5-fluorouridine; 5-FU; 5-fluorouracil; AEs; adverse events; AML; acute promyelocytic leukemia; AU; arbitrary unit; CDA; cytidine deaminase; CES; carboxylesterase; DPD; dihydropyrimidine dehydrogen
Everolimus-based combination therapies for HR+, HER2â metastatic breast cancer
Keywords: سرطان متاستاتیک سینه; Everolimus; Metastatic breast cancer; Endocrine therapy; Hormone receptor-positive;
Treatment Patterns and Outcomes of Patients With Metastatic ER+/HER-2â Breast Cancer: AÂ Multicountry Retrospective Medical Record Review
Keywords: سرطان متاستاتیک سینه; Chemotherapy; Endocrine; ER+; HER2â; Metastatic breast cancer;
Multiple modes of action of eribulin mesylate: Emerging data and clinical implications
Keywords: سرطان متاستاتیک سینه; Eribulin; Antimitotic; Tumor microenvironment; Survival benefit; Epithelial-to-mesenchymal transition; Metastatic breast cancer;
Ongoing unmet needs in treating estrogen receptor-positive/HER2-negative metastatic breast cancer
Keywords: سرطان متاستاتیک سینه; Metastatic breast cancer; Estrogen receptor-positive/HER2â breast cancer; Unmet needs; Palbociclib;
Increased risk of SSEs in bone-only metastatic breast cancer patients treated with zoledronic acid
Keywords: سرطان متاستاتیک سینه; b-MBC; bone-metastasized breast cancer; BP; bisphosphonate; CI; confidence interval; ER; estrogen receptor; HER2; human epidermal growth factor receptor 2; HR; hormone receptor; MBC; metastatic breast cancer; OR; odds ratio; PgR; progesterone receptor; SR
More than just the median: Calculating survival times for patients with HER2 positive, metastatic breast cancer using data from recent randomised trials
Keywords: سرطان متاستاتیک سینه; Estimating survival times; HER2-positive; Metastatic breast cancer;
2003-2013, a valuable study: Autologous tumor lysate-pulsed dendritic cell immunotherapy with cytokine-induced killer cells improves survival in stage IV breast cancer
Keywords: سرطان متاستاتیک سینه; Dendritic cell; Immunotherapy; Cytokine-induced killer; Stage IV breast cancer; DFS; OS; DC; dendritic cell; CIK; cytokine induced killer; DFS; disease-free survival; OS; overall survival; MBC; metastatic breast cancer; PBMCs; peripheral blood mononuclear
Men and women show similar survival outcome in stage IV breast cancer
Keywords: سرطان متاستاتیک سینه; Metastatic breast cancer; Male; Female; Survival; Metastatic patterns;
Impact of Primary Tumor Surgery in Stage IV Male Breast Cancer
Keywords: سرطان متاستاتیک سینه; Metastatic breast cancer; Primary tumor surgery; Stage IV cancer; Survival;
Original ResearchPatients' preference of trastuzumab administration (subcutaneous versus intravenous) in HER2-positive metastatic breast cancer: Results of the randomised MetaspHer study
Keywords: سرطان متاستاتیک سینه; Trastuzumab; Subcutaneous; Preference; Metastatic breast cancer;
ESR1 mutations: Moving towards guiding treatment decision-making in metastatic breast cancer patients
Keywords: سرطان متاستاتیک سینه; ESR1 mutations; Metastatic breast cancer; Endocrine resistance; Cell-free DNA;
Phase II, multicentre, randomised trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy in patients with HER2-negative metastatic breast cancer
Keywords: سرطان متاستاتیک سینه; Metastatic breast cancer; Eribulin; Paclitaxel; Gemcitabine; Chemotherapy;
Phase I Trial of Everolimus and Capecitabine in Metastatic HER2â Breast Cancer
Keywords: سرطان متاستاتیک سینه; 5-FU; Metastatic breast cancer; mTOR inhibitor; Phase 1; Tolerable;
Original ResearchReal-world and trial-based cost-effectiveness analysis of bevacizumab in HER2-negative metastatic breast cancer patients: a study of the Southeast Netherlands Breast Cancer Consortium
Keywords: سرطان متاستاتیک سینه; Metastatic breast cancer; Bevacizumab; Cost-effectiveness analysis; Real-world; Trial based; Cost-benefit analysis;
Original ResearchExternal validation of a published nomogram for prediction of brain metastasis in patients with extra-cerebral metastatic breast cancer and risk regression analysis
Keywords: سرطان متاستاتیک سینه; Metastatic breast cancer; Brain metastases; Nomogram; External validation; Competing risk analysis; Preventive/prophylactic treatment;
Original ResearchBevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation
Keywords: سرطان متاستاتیک سینه; Bevacizumab; Metastatic breast cancer; Predictive; Biomarker; Double-blind; VEGF-A; Weekly paclitaxel; Prospective;
Patient-reported Quality of Life and Treatment Satisfaction in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer
Keywords: سرطان متاستاتیک سینه; Advanced breast cancer; metastatic breast cancer; health-related quality of life; real-world; treatment satisfaction;
Treatment of metastatic breast cancer in EU: Analysis of market research data from 4Q2013 till 3Q2014
Keywords: سرطان متاستاتیک سینه; Metastatic breast cancer; Chemotherapy; Marketing research; Guidelines;
Health-related quality of life in patients with locally recurrent or metastatic breast cancer treated with etirinotecan pegol versus treatment of physician's choice: Results from the randomised phase III BEACON trial
Keywords: سرطان متاستاتیک سینه; Advanced breast cancer; Etirinotecan pegol; Metastatic breast cancer; NKTR-102; Quality of life;
A real-world study on implementation of bevacizumab in a cohort of HER2-negative metastatic breast cancer patients: A study of the Southeast Netherlands Breast Cancer Consortium
Keywords: سرطان متاستاتیک سینه; Metastatic breast cancer; Bevacizumab; Taxanes; Real world; Implementation; Effectiveness;
The Prognostic Value of HER2-Positive Circulating Tumor Cells in Breast Cancer Patients: A Systematic Review and Meta-Analysis
Keywords: سرطان متاستاتیک سینه; Metastatic breast cancer; Non-metastatic breast cancer; Progression-free survival; Survival; Therapy resistance;
Chemotherapy for advanced HER2-negative breast cancer: Can one algorithm fit all?
Keywords: سرطان متاستاتیک سینه; Metastatic breast cancer; HER2 negative; Chemotherapy; Personalized therapy; Treatment algorithm;
Yttrium-90 Radioembolization for Breast Cancer Liver Metastases
Keywords: سرطان متاستاتیک سینه; CTC; circulating tumor cell; GGT; γ-glutamyltransferase; MBC; metastatic breast cancer; OS; overall survival; PFS; progression-free survival; RECIST; Response Evaluation Criteria In Solid Tumors; WHO; World Health Organization;
Sanctuary site leptomeningeal metastases in HER-2 positive breast cancer: A review in the era of trastuzumab
Keywords: سرطان متاستاتیک سینه; Metastatic breast cancer; HER-2 positive; Leptomeningeal metastases; Intrathecal trastuzumab (Herceptin);